相关实验视频

Updated: Sep 14, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

含有CD80的多功能T细胞激活剂增强了前列腺癌治疗的效果

Disen Nie¹, Yao Jiang¹, Hui Li²

¹Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.

Cancer immunology, immunotherapy : CII

|July 23, 2025

概括

改造的TriTE-N13,一种新的T细胞参与者 (TCE),增强了T细胞与CD80的共同刺激,以克服瘤微环境抑制. 这种双特异性抗体在活体中显示出对前列腺癌的卓越疗效.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

T细胞参与者 (TCE) 将T细胞重定向到瘤,但由于免疫抑制性瘤微环境 (TME),在固体瘤中面临限制.
需要增强的TCE来克服TME诱导的T细胞抑制,以改善固体瘤治疗.

研究的目的:

设计和评估一种新的三功能抗体,TriTE-N13,结合CD80进行共刺激,以增强T细胞对抗前列腺癌的活性.
在前列腺癌模型中评估TriTE-N13的体外和体内疗效和安全性.

主要方法:

通过基因编辑和真核体表达,设计了一个完全人性化的融合抗体,TriTE-N13.
在2D和3D模型中对PSMA+瘤细胞进行了体外T细胞激活,增殖和细胞毒性评估.
在前列腺癌异位移植的人类免疫恢复小鼠模型中评估了体内抗瘤疗效和安全性.

主要成果:

TriTE-N13证明了强大的人类T细胞激活和高亲和度与PSMA和CD3结合.
在实验室中观察到有效的T细胞依赖性细胞毒性对PSMA阳性前列腺癌细胞.
与常规双特异性TCE相比,TriTE-N13在体内实现了显著更大的瘤体积减少,特别是在已建立的瘤中.

结论:

结合CD80协同刺激,可以显著提高TCE对固体瘤的抗瘤功效.
TriTE-N13代表了一个有前途的免疫治疗候选人,用于晚期前列腺癌.

关键词:

CD8080 CD8080 CD8080 CD8080 CD8080 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 对于PSMA/CD3抗原来说,这是一个很大的问题.前列腺癌是什么意思前列腺癌是什么意思这种T细胞的参与者是T细胞.三种特异性抗体.

更多相关视频

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...